Amylin Pharmaceuticals Announces Public Offering of Common Stock
March 27 2006 - 7:30AM
PR Newswire (US)
SAN DIEGO, March 27 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (NASDAQ:AMLN) today announced that it has
filed a preliminary prospectus supplement to a shelf registration
statement with the Securities and Exchange Commission relating to a
proposed public offering of 8,500,000 shares of its common stock.
The underwriters will be granted the right to purchase up to an
additional 1,275,000 shares of common stock to cover
over-allotments, if any. All of the shares are being sold by Amylin
Pharmaceuticals. Morgan Stanley & Co. Incorporated is acting as
the sole bookrunning and joint lead manager for the offering.
Goldman, Sachs & Co. is acting as a non-bookrunning joint-lead
manager of the offering. Co-managers for the offering are Bear,
Stearns & Co. Inc. and Lehman Brothers Inc. These securities
may not be sold nor may offers to buy be accepted prior to the time
that the prospectus supplement is final. The common stock is being
offered in connection with a distribution by the issuer and
represents new financing. Amylin Pharmaceuticals is a
biopharmaceutical company committed to improving lives through the
discovery, development and commercialization of innovative
medicines. Copies of the preliminary prospectus supplement may be
obtained from the Prospectus Department of Morgan Stanley & Co.
Incorporated (1585 Broadway, New York, New York 10036, phone
212-761-6775, fax 212-761-0211). DATASOURCE: Amylin
Pharmaceuticals, Inc. CONTACT: Mark G. Foletta, Vice President,
Finance and Chief Financial Officer of Amylin Pharmaceuticals,
Inc., +1-858-552-2200 Web site: http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024